CRISTIE FAIRCLOTH: Open Payments
NPI 1487800314 · CHARLOTTE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$586 in 29 payments from 11 companies in 2025. Trend: 2023 $454 · 2024 $686 · 2025 $586
Food & beverage: $586
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $195 |
| E.R. Squibb & Sons, L.L.C. | 4 | $94 |
| Neurocrine BioSciences, Inc. | 2 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| ABBVIE INC. | 2 | $39 |
| Neos Therapeutics, LP | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
| Alkermes, Inc. | 2 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
Products named: REXULTI, COBENFY, INGREZZA, AUSTEDO XR, VRAYLAR, Adzenys XR-ODT, TRINTELLIX, SPRAVATO.
Industry payments across NC — which companies pay providers there.
